In addition to the significant expense categories included within consolidated net loss presented on the Company's Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses which are presented to the Company's CODM for review:


	Three Months Ended March 31,
	2026		2025
External clinical development expenses (1)
SBI-100	$	—	$	2,241
nimacimab	5,329,238		4,915,030
Total External clinical development expenses	5,329,238		4,917,271
Personnel related and stock-based compensation	1,712,798		1,337,750
Other research and development expenses (2)	893,644		942,236
Total research and development expenses	$	7,935,680	$	7,197,257

(1) External clinical development expenses include expenses for clinical trial costs and clinical manufacturing.

(2) Other research and development expenses include expenses for travel and entertainment, consulting and advisory, discovery research and development, and general business expenses.